Sanofi to create new vaccines facility in Canada

Sanofi has announced plans to develop a new state-of-the-art vaccine manufacturing facility in Canada to support its vaccines division Sanofi Pasteur.

The new EUR 350 million (GBP 305.02 million) site will be created at Sanofi Pasteur's Canadian headquarters in Toronto, Ontario, and will help the company meet the growing demand for five-component acellular pertussis antigens.

Upon completion in 2021, the new building will also be equipped to produce the antigens used in the diphtheria and tetanus vaccines, making it easier for Sanofi Pasteur to serve the public health needs of Canada and the global community.

This investment will also strengthen the company's commitment to Canada, with Sanofi citing the country's strong legacy in the research and development of vaccines as a key factor behind the project.

Philippe Luscan, executive vice-president for global industrial affairs at Sanofi, said: "This project is one of the most important investments for the Sanofi global industrial network. It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.